drugset / Trial / NCT00429962

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

NCT00429962

Phase 3 Completed 40 enrolled University Hospital, Basel, Switzerland
RandomizedParallel-groupTriple-blindTreatment

Summary

This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD

Timeline

Start
2006-07
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody Intravitreal
Subject Verteporfin Other / unclassified Intravenous